- Home
- ONCO vs TNFA Comparison
ONCO vs TNFA Comparison
Compare ONCO & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- TNFA
- Stock Information
- Founded
- ONCO 2018
- TNFA 2014
- Country
- ONCO United States
- TNFA United States
- Employees
- ONCO N/A
- TNFA 2
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- TNFA
- Sector
- ONCO Health Care
- TNFA
- Exchange
- ONCO Nasdaq
- TNFA NYSE
- Market Cap
- ONCO 1.8M
- TNFA 1.6M
- IPO Year
- ONCO 2022
- TNFA N/A
- Fundamental
- Price
- ONCO $4.23
- TNFA $0.11
- Analyst Decision
- ONCO
- TNFA
- Analyst Count
- ONCO 0
- TNFA 0
- Target Price
- ONCO N/A
- TNFA N/A
- AVG Volume (30 Days)
- ONCO 229.9K
- TNFA 4.8M
- Earning Date
- ONCO 08-28-2025
- TNFA 08-18-2025
- Dividend Yield
- ONCO N/A
- TNFA N/A
- EPS Growth
- ONCO N/A
- TNFA N/A
- EPS
- ONCO N/A
- TNFA N/A
- Revenue
- ONCO $1,925,313.00
- TNFA N/A
- Revenue This Year
- ONCO N/A
- TNFA N/A
- Revenue Next Year
- ONCO N/A
- TNFA N/A
- P/E Ratio
- ONCO N/A
- TNFA N/A
- Revenue Growth
- ONCO 153.70
- TNFA N/A
- 52 Week Low
- ONCO $3.82
- TNFA $0.10
- 52 Week High
- ONCO $1,190.00
- TNFA $2.16
- Technical
- Relative Strength Index (RSI)
- ONCO 40.01
- TNFA 32.59
- Support Level
- ONCO $4.19
- TNFA $0.11
- Resistance Level
- ONCO $5.17
- TNFA $0.14
- Average True Range (ATR)
- ONCO 0.45
- TNFA 0.02
- MACD
- ONCO 0.07
- TNFA 0.00
- Stochastic Oscillator
- ONCO 21.76
- TNFA 12.04
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.